Latest Comments

With FDA approval secured, Flexion’s Zilretta poised to shake up knee osteoarthritis marketplace

With FDA approval secured, Flexion’s Zilretta poised to shake up knee osteoarthritis marketplace

Repealing the ACA: the Graham-Cassidy Bill’s impact on expanded Medicaid coverage

Repealing the ACA: the Graham-Cassidy Bill’s impact on expanded Medicaid coverage

Safety concerns cloud Ocaliva’s future prospects in NASH

Safety concerns cloud Ocaliva’s future prospects in NASH

GSK Announces Planned Regulatory Filing of Nucala – Will the IL-5 Inhibitor Mark the First Approved Biologic for COPD?

GSK Announces Planned Regulatory Filing of Nucala – Will the IL-5 Inhibitor Mark the First Approved Biologic for COPD?

Is the Neulasta molecule too complex for biosimilar developers to crack?

Is the Neulasta molecule too complex for biosimilar developers to crack?

Novel Hyperkalemia Agents Race Toward the European CKD Market

Novel Hyperkalemia Agents Race Toward the European CKD Market

Ten-year old NICE restrictions on Velcade limit patient access to next-gen therapies

Ten-year old NICE restrictions on Velcade limit patient access to next-gen therapies

Why has the Industry seen higher numbers of Drug Designations than ever before?

Why has the Industry seen higher numbers of Drug Designations than ever before?

ESC Congress Barcelona 2017 Highlights – What is the Role of Monotherapies in the Treatment of PAH Patients?

ESC Congress Barcelona 2017 Highlights – What is the Role of Monotherapies in the Treatment of PAH Patients?

High Multiple Sclerosis Costs Are Attracting Attention From US Lawmakers

High Multiple Sclerosis Costs Are Attracting Attention From US Lawmakers

Despite Humira patent expiry, Abbvie is poised to remain a market leader in Crohn’s disease

Despite Humira patent expiry, Abbvie is poised to remain a market leader in Crohn’s disease

The future of vaccines – could they really grow on trees?

The future of vaccines – could they really grow on trees?

PARP inhibitors are set to become the new standard of care in BRCA1/2-mutated pancreatic adenocarcinoma

PARP inhibitors are set to become the new standard of care in BRCA1/2-mutated pancreatic adenocarcinoma

Anti-nerve growth factor antibodies expected to drive osteoarthritis market growth

Anti-nerve growth factor antibodies expected to drive osteoarthritis market growth

Could the first new sickle cell drug in 20 years provide hope for sufferers?

Could the first new sickle cell drug in 20 years provide hope for sufferers?

Novartis launches first smartphone-based study in MS

Novartis launches first smartphone-based study in MS

Amgen and Array BioPharma partnership: creating waves in autoimmune disorder market

Amgen and Array BioPharma partnership: creating waves in autoimmune disorder market

Fighting obesity: Past and future treatments

Fighting obesity: Past and future treatments

A vaccine for Lyme disease – second time lucky?

A vaccine for Lyme disease – second time lucky?

Breakthroughs for orphan designated hematological drugs could earn big revenues

Breakthroughs for orphan designated hematological drugs could earn big revenues

Tensions Rise as UK Pharma Industry Takes Government to Court

Tensions Rise as UK Pharma Industry Takes Government to Court